All Stories

  1. Impact and cost-effectiveness of the 6-month BPaLM regimen for rifampicin-resistant tuberculosis in Moldova: A mathematical modeling analysis
  2. Comparison of QTc interval changes in drug-resistant tuberculosis patients on delamanid-containing regimens versus shorter treatment regimens
  3. A new method for detecting mixed Mycobacterium tuberculosis infection and reconstructing constituent strains provides insights into transmission
  4. The recent rapid expansion of multidrug resistant Ural lineage Mycobacterium tuberculosis in Moldova
  5. Identifying local foci of tuberculosis transmission in Moldova using a spatial multinomial logistic regression model
  6. Identification of differentially recognized T cell epitopes in the spectrum of tuberculosis infection
  7. Predicting stringent QuantiFERON-TB Gold Plus conversions in contacts of tuberculosis patients
  8. Impact and cost-effectiveness of the 6-month BPaLM regimen for rifampicin-resistant tuberculosis: a mathematical modeling analysis
  9. Geographical analysis and evaluation of M. tuberculosis genome sequencing at the national level
  10. Pharmacokinetics of antitubercular drugs in patients hospitalized with HIV-associated tuberculosis: a population modeling analysis
  11. Predicting resistance to fluoroquinolones among patients with rifampicin-resistant tuberculosis using machine learning methods
  12. Phylogeography and transmission of M. tuberculosis in Moldova: A prospective genomic analysis
  13. Integrating landmark modeling framework and machine learning algorithms for dynamic prediction of tuberculosis treatment outcomes
  14. Detection of isoniazid, fluoroquinolone, ethionamide, amikacin, kanamycin, and capreomycin resistance by the Xpert MTB/XDR assay: a cross-sectional multicentre diagnostic accuracy study
  15. Benchmarking the empirical accuracy of short-read sequencing across the M. tuberculosis genome
  16. Emergence of bedaquiline-resistance in a high-burden country of tuberculosis
  17. Evolution and emergence of multidrug-resistant Mycobacterium tuberculosis in Chisinau, Moldova
  18. Rapid Detection of Extensively Drug-Resistant Tuberculosis in Clinical Samples Using a Novel Tabletop Platform: Protocol for a Prospective Clinical Study
  19. Phylogeography and transmission of M. tuberculosis in Moldova
  20. Clinical evaluation of the Xpert MTB/XDR assay for rapid detection of isoniazid, fluoroquinolone, ethionamide and second-line drug resistance: A cross-sectional multicentre diagnostic accuracy study
  21. Genomic sequence characteristics and the empiric accuracy of short-read sequencing
  22. Laboratory costs of diagnosing TB in a high multidrug-resistant TB setting
  23. Evolution and emergence of multidrug-resistant Mycobacterium tuberculosis in Chisinau, Moldova
  24. Rapid Detection of Extensively Drug-Resistant Tuberculosis in Clinical Samples Using a Novel Tabletop Platform: Protocol for a Prospective Clinical Study (Preprint)
  25. Molecular Detection of Mycobacterium tuberculosis in Oral Mucosa from Patients with Presumptive Tuberculosis
  26. Impact of bedaquiline on treatment outcomes of multidrug-resistant tuberculosis in a high-burden country
  27. Automated high-throughput digital fluorescence microscopy for TB diagnosis
  28. A retrospective genomic analysis of drug-resistant strains of M. tuberculosis in a high-burden setting, with an emphasis on comparative diagnostics and reactivation and reinfection status
  29. A retrospective genomic analysis of drug-resistant strains of M. tuberculosis in a high-burden setting, with an emphasis on comparative diagnostics and reactivation and reinfection status.
  30. Prediction of multiple drug resistant pulmonary tuberculosis against drug sensitive pulmonary tuberculosis by CT nodular consolidation sign
  31. Assessing tuberculosis control priorities in high-burden settings: a modelling approach
  32. Failing treatment of multidrug-resistant tuberculosis: a matter of definition
  33. Building a tuberculosis-free world: The Lancet Commission on tuberculosis
  34. Acute phase proteins and IP-10 as triage tests for the diagnosis of tuberculosis: systematic review and meta-analysis
  35. Beyond the SNP Threshold: Identifying Outbreak Clusters Using Inferred Transmissions
  36. Clinical Management of Multidrug-Resistant Tuberculosis in 16 European Countries
  37. Beyond the SNP threshold: identifying outbreak clusters using inferred transmissions
  38. Cost analysis of rapid diagnostics for drug-resistant tuberculosis
  39. Reply: Benefit of the Shorter Multidrug-Resistant Tuberculosis Treatment Regimen in California and Modified Eligibility Criteria
  40. Tuberculosis Treatment Outcomes in Europe: Based on Treatment Completion, Not Cure
  41. High-dose isoniazid in the shorter-course multidrug-resistant tuberculosis regimen in the Republic of Moldova
  42. Lack of evidence of isoniazid efficacy for the treatment of MDR/XDR-TB in the presence of thekatG315T mutation
  43. The TB Portals: database for M/XDR TB
  44. Treatment outcomes of MDR-TB and HIV co-infection in Europe
  45. FATE: the new partnership to Fight Against TB in Central and Eastern Europe
  46. Genomic analysis of globally diverse Mycobacterium tuberculosis strains provides insights into the emergence and spread of multidrug resistance
  47. MDR-TB in Eastern Europe in the era of the TB elimination action framework
  48. Armed conflict and population displacement as drivers of the evolution and dispersal of Mycobacterium tuberculosis
  49. Mycobacterium tuberculosis lineage 4 comprises globally distributed and geographically restricted sublineages
  50. Limited Benefit of the New Shorter Multidrug-Resistant Tuberculosis Regimen in Europe
  51. Urgent need to rethink treatment outcome definitions in tuberculosis
  52. Shedding light on the performance of a pyrosequencing assay for drug-resistant tuberculosis diagnosis
  53. Errata
  54. Rapid Drug Susceptibility Testing of Drug-Resistant Mycobacterium tuberculosis Isolates Directly from Clinical Samples by Use of Amplicon Sequencing: a Proof-of-Concept Study
  55. A performance evaluation of MTBDRplus version 2 for the diagnosis of multidrug-resistant tuberculosis
  56. Frequency and Distribution of Tuberculosis Resistance-Associated Mutations between Mumbai, Moldova, and Eastern Cape
  57. In reply
  58. MTBDRplusand MTBDRslAssays: Absence of Wild-Type Probe Hybridization and Implications for Detection of Drug-Resistant Tuberculosis
  59. Nosocomial transmission of multidrug-resistant tuberculosis
  60. Beyond multidrug-resistant tuberculosis in Europe: a TBNET study
  61. Predicting differential rifamycin resistance in clinical Mycobacterium tuberculosis isolates by specific rpoB mutations
  62. Out-patient MDR-TB care in Moldova
  63. Transmission ofmycobacterium tuberculosisUral 163-15 lineage causing multidrug-resistant tuberculosis among hospitalized patients
  64. Performance Comparison of Three Rapid Tests for the Diagnosis of Drug-Resistant Tuberculosis
  65. Detection of Low-Level Mixed-Population Drug Resistance in Mycobacterium tuberculosis Using High Fidelity Amplicon Sequencing
  66. Phenotypic and genotypic diversity in a multinational sample of drug-resistant Mycobacterium tuberculosis isolates
  67. Combined Antigen-Specific Interferon-γ and Interleukin-2 Release Assay (FluoroSpot) for the Diagnosis of Mycobacterium tuberculosis Infection
  68. Multidrug-Resistant Tuberculosis in Europe, 2010–2011
  69. Prognostic significance of novel katG mutations in Mycobacterium tuberculosis
  70. Evolutionary history and global spread of the Mycobacterium tuberculosis Beijing lineage
  71. Novel katG mutations causing isoniazid resistance in clinical M. tuberculosis isolates
  72. The Global Consortium for Drug-resistant Tuberculosis Diagnostics (GCDD): design of a multi-site, head-to-head study of three rapid tests to detect extensively drug-resistant tuberculosis
  73. Evaluation of Pyrosequencing for Detecting Extensively Drug-Resistant Mycobacterium tuberculosis among Clinical Isolates from Four High-Burden Countries
  74. Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement
  75. High risk and rapid appearance of multidrug resistance during tuberculosis treatment in Moldova
  76. Second-line drug susceptibility breakpoints for Mycobacterium tuberculosis using the MODS assay
  77. Predicting Extensively Drug-Resistant Mycobacterium tuberculosis Phenotypes with Genetic Mutations
  78. Publisher's Expression of Concern: Geographical Differences Associated with SNPs in Nine Gene Targets among Resistant Clinical Isolates of Mycobacterium tuberculosis
  79. Geographical Differences Associated with Single-Nucleotide Polymorphisms (SNPs) in Nine Gene Targets among Resistant Clinical Isolates of Mycobacterium tuberculosis
  80. Risk factors and timing of default from treatment for non-multidrug-resistant tuberculosis in Moldova
  81. Periodontal Disease Is an Independent Predictor of Intracardiac Calcification
  82. Assessing spatial heterogeneity of multidrug-resistant tuberculosis in a high-burden country
  83. Middle‐of‐the‐night PCI does not affect subsequent day PCI success and complication rates by the same operator
  84. First Evaluation of an Improved Assay for Molecular Genetic Detection of Tuberculosis as Well as Rifampin and Isoniazid Resistances
  85. Complications related to access site after percutaneous coronary interventions
  86. Can total cardiac calcium predict the coronary calcium score?
  87. Assessment Of The Nosocomial Transmission Of MDR TB In Moldova Using DNA Fingerprinting Of M.tuberculosis
  88. Relationship between intensive diuresis and QRS morphology change
  89. Increasing tuberculosis case detection: lessons from the Republic of Moldova